(Q37949201)

English

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.

scientific article published on 25 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

multiple myeloma

1 reference

based on heuristic

inferred from title

Ibrahim Yakoub-Agha

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Herve Avet-Loiseau

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

B Mohty

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

J El-Cheikh

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

P Moreau

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M Mohty

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

25 October 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

73-85

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22024721%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

https://scigraph.springernature.com/pub.10.1038/leu.2011.310

0 references

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Recent major improvement in long-term survival of younger patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

The use of novel agents in the treatment of relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

The medical review article: state of the science

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Checklists for review articles

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Importance of achieving a complete response in multiple myeloma, and the impact of novel agents

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

The role of complete response in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

CR represents an early index of potential long survival in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Relapse/Refractory myeloma patient: potential treatment guidelines.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Ultra high-risk myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Repeat administration of high dose melphalan in relapsed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Treatment of relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Transplantation as salvage therapy for high-risk patients with myeloma in relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Emerging therapies for the treatment of relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Impact of early relapse after auto-SCT for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Renal insufficiency and failure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Meeting the unmet needs in anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

21 January 2018

Relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Toward deeper response in MM

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged overall survival with second on-demand autologous transplant in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Re-transplantation after bortezomib-based therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.310

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37949201&oldid=2117479113"